Cheapest Compounded Tirzepatide in 2026

Released August 8, 2026 · Last reviewed November 9, 2026

Every compounded tirzepatide programme priced all-in, with the plan term named on each figure.

On October 15, 2026, compounded tirzepatide cost $86 to $299 a month across the 24 programmes we priced (median $144). NexLife, our featured provider, charges $115 a month on its 12-month plan ($1,380 total) and $129 month-to-month, the same at every dose; Mondae prints a lower standing month-to-month price, and Eden's is the same.

That qualifier is the point. Most published tirzepatide comparisons quote a figure without saying whether it requires a prepaid year, whether a membership is billed separately, or whether it is a microdose sitting below every dose the pivotal trials studied. Those three distortions all push the advertised number down, and they compound.

What the programmes actually charge

Found lists compounded tirzepatide at $169 a month. 12-month PREPAID. Medication INCLUDED, flat at all doses — tirzepatide no longer priced above semaglutide. 6-month ~$199; month-to-month $289. Provider Reported

NexLife lists compounded tirzepatide at $115 a month. Standard injection, 12-month plan ($1,380 total). 6-month $119; 3-month $125; month-to-month $129. No membership fee, flat at every covered dose. Verified

NexLife lists compounded tirzepatide at $199 a month. ODT (orally disintegrating tablet), 12-month plan ($2,388 total). NO TRIAL HAS TESTED THIS DOSAGE FORM. Verified

Oak Longevity lists compounded tirzepatide at $199 a month. Flat across all dosages, no subscription. ~$233-$299 month-to-month. Provider Reported

Shed lists compounded tirzepatide at $229 a month. 'GLP-1 Liquid Drops' (was $419). 2-month minimum. Provider Reported

Shed lists compounded tirzepatide at $245 a month. 12-month plan paid upfront. 6-month $279; month-to-month $349. INCREASES at higher doses. Provider Reported

How to read any tirzepatide price

Ask three questions of every figure. Is it the month-to-month rate or a prepaid one? Does it include every mandatory recurring fee, or is a membership billed separately? And is it a standard therapeutic dose or a microdose? A price that survives all three questions is comparable to another price. One that does not is a marketing number.

Full column-by-column breakdown at the tirzepatide pricing comparison.

Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to any brand-name product. FDA does not review compounded preparations for safety, effectiveness or manufacturing quality before marketing. This is consumer price research, not medical advice. Prices captured 2026-09-04.

The numbers behind this page

The tirzepatide price range, stated precisely

Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.

The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.

Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.

Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.

What we do not claim in tirzepatide

On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced.

We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.

And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.

Reading the price against the market

What the plan term is worth

Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.

Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.

Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.

We show month-to-month and prepaid figures side by side for that reason. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.

Questions this page answers

Does compounded tirzepatide cost more at higher doses?

At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.

Why is microdosed tirzepatide cheaper?

Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.

What does compounded tirzepatide cost per month in October 2026?

As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.

What does compounded tirzepatide normally cost?

$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.